Pioglitazone HCl

• CAT Number: A000405
• CAS Number: 112529-15-4
• Molecular Formula: C19H20N2O3S.HCl
• Molecular Weight: 392.90
• Purity: ≥95%
• Synonyms: AD-4833, U-72107E
• Target: Vitamin D Related/Nuclear Receptor
• Solubility: >19.7mg/mL in DMSO
• Storage: 3 years -20C powder
• IUPAC Name: 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione;hydrochloride
• InChI: InChI=1S/C19H20N2O3S.ClH/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17;/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23);1H
• InChIKey: GHUUBYQTCDQWRA-UHFFFAOYSA-N
• SMILES: CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3.Cl

Pioglitazone HCl（Cat No.:A000405）is a thiazolidinedione-class drug used primarily to treat type 2 diabetes. It works by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), a nuclear receptor involved in regulating glucose and lipid metabolism. Through PPAR-γ activation, Pioglitazone increases insulin sensitivity in peripheral tissues, promoting glucose uptake and reducing blood sugar levels. Additionally, it helps improve lipid profiles by lowering triglycerides and increasing HDL cholesterol. Pioglitazone is commonly prescribed for managing hyperglycemia in patients with type 2 diabetes, often in combination with other antidiabetic medications to enhance therapeutic outcomes.

Reference

1.Sakamoto, Junichi, et al. "Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone." Biochemical and biophysical research communications 278.3 (2000): 704-711.
2.Li, Xinbao, et al. "Preferential solvation of pioglitazone hydrochloride in some binary co-solvent mixtures according to the inverse Kirkwood–Buff integrals method." The Journal of Chemical Thermodynamics 110 (2017): 218-226.
3.Xing, Bin, et al. "Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt." Journal of Neuroinflammation 5.1 (2008): 1-11.
4.Sugiyama, Y., et al. "Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats." Arzneimittel-forschung 40.3 (1990): 263-267.